European Academy of Dermatology and Venereology

EADV report shows that two JAK inhibitors reverses alopecia areata in some patients.

Potential new treatment with targeted monoclonal antibodies offers new hope for cutaneous lymphoma patients.

Clinicians are more likely to correctly identify the lesions’ underlying cause with careful observation rather than with several lab tests.

Patients who achieve complete skin clearance of psoriasis experience a noticeable difference in quality of life and work productivity.

With immunotherapy as a key treatment for melanoma, dermatologists should be prepared to treat its cutaneous side effects and refer for adrenal sufficiency, uveitis, thyroid disease and other non-cutaneous side effects.

Checkpoint inhibitors have clearly changed the prognosis of melanoma, yet the search for evidence-based answers to these and other questions regarding their use continues, experts report at EADV this week.

Patients who undergo treatment with ixekizumab experience greater nail psoriasis improvement than individuals treated with ustekinumab.

Risankizumab performed better in treating psoriasis that appears on the nails, hands and feet, palms and scalp sores.

The European Academy of Dermatology and Venerology (EADV) 2018 meeting takes this week in Paris. Visit our EADV conference news site to follow the developments from Paris.